WO1998045713A1 - Verfahren zur bestimmung von aktivierten blutgerinnungsfaktoren in plasma und plasmaderivaten - Google Patents
Verfahren zur bestimmung von aktivierten blutgerinnungsfaktoren in plasma und plasmaderivaten Download PDFInfo
- Publication number
- WO1998045713A1 WO1998045713A1 PCT/EP1998/001264 EP9801264W WO9845713A1 WO 1998045713 A1 WO1998045713 A1 WO 1998045713A1 EP 9801264 W EP9801264 W EP 9801264W WO 9845713 A1 WO9845713 A1 WO 9845713A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasma
- factor
- activated
- thrombin
- tissue factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Definitions
- the invention relates to a method for determining activated blood coagulation factors in plasma and plasma derivatives.
- Blood coagulation factors are normally enzymatically inactive proenzymes, which are converted into their biologically active form by limited proteolytic cleavage.
- prothrombin factor II
- thrombin factor Ha
- Thrombin also activates factor XIII, which crosslinks fibrin into a stable clot. This physiological activation is desirable in most cases.
- tissue factor is an integral membrane protein that binds both factor VII and factor VIII with high affinity
- tissue factor also catalyzes the activation of factor VII to factor VIIa.
- tissue factor a mutated form of the tissue factor is described, the amino acid sequence around that section of the
- 2Q protein is shortened, which is responsible for the binding to the membrane.
- the now soluble tissue factor tTF can bind factor VIII and is fully active in a coagulation test. However, he has lost the ability to auto-catalyze from factor VII to factor VIIa. Therefore you can with help
- a coagulation test which is known and described under the name NAPPT 35 (non-activated partial prothrombine time), is prescribed as a standard test for prothrombin complex PPSB (see: HS KINGDON et al .; Potentially thrombogenic materials in factor IX concentrates; Thro b. Diath. Haemorrh. 1975; 617-631).
- a sample amount of the plasma or plasma derivative to be examined is incubated with activated prothrombin complex and procoagulatory phospholipid vesicles, containing the latter integrated tissue factor, and the formation of thrombin is started by adding a suitable amount of Ca ions,
- the thrombin formation is ended and the amount of thrombin formed is determined by known methods.
- the new test method works with materials that can be produced in practically unlimited quantities and can be stored for a long time, so that tests can be carried out without delay because of the formation of a platelet suspension.
- the new test measures thrombin formation in defibrinated plasma in the presence of activated factors.
- the amount of thrombin formed is measured using known methods by cleaving a synthetic substrate, for example the known S 2238 (see HP Schwarz et al .; Kyoto Satellite Symposia of Xllth Congress of ISTH; Kyoto, Japan, 1989; p. 34 - abstract). The resulting color is measured photometrically.
- a test batch contains a small amount of a n e and activated prothrombin prokoagu- latowitz phospholipid vesicles, the latter being integrated tissue factor.
- the presence of the activated prothrombin complex is chosen because, because of the auto-catalytic nature of thrombin formation with very small amounts of activated factors, the start-up phase (lag phase) of thrombin formation would be of different lengths. It would not be precisely defined after which incubation times one would have to measure the thrombin formation.
- the tissue factor to be used is produced from biogenic starting material, acetone dry powder in particular being extracted from the bovine brain by a detergent-containing solution.
- the tissue factor is mixed with phosphatidylserine and phosphatidylcholine in a detergent-containing solution for incorporation into procoagulatory phospholipid vesicles and integrated into the procoagulatory phospholipid vesicles by dialysis.
- Ancrod (venom of the snake species Ankistrodon r odostoma; Sig a Chemical Co .; Art. No. A 5042) is mixed with distilled water diluted to 10 U / ml. 1 ml of human plasma from normal donors is mixed with 10 ⁇ l of Ancrod solution, incubated for 1 hour at 37 ° C., rapidly cooled to -70 ° C., warmed again to 37 ° C. and centrifuged. The supernatant, defibrinated plasma, is stored at room temperature and must be used within 10 minutes The defibrinated plasma can also be frozen in portions and contains only negligible traces of thrombin.
- cryogen supernatant 50 ml of normal plasma are frozen, thawed at 4 ° C. overnight and 15 min. centrifuged. The supernatant is "cryogen supernatant"; 0.5 units of heparin per ml of cryogen supernatant are added to the latter.
- DEAE-Sephadex is allowed to swell in 1 M NaCl solution for 15 min at room temperature (21 - 24 ° C) or overnight at 4 ° C (20 mg dry matter to 2 ml solution), by repeated filtering through a nylon mesh and resuspending in an equilibration puff - he equilibrate. Heparin-binding proteins are adsorbed from the supernatant on the ion exchanger by incubation at 4 ° C. for one hour. 40 ml of cryogen supernatant are added to equilibrated DEAE-Sephadex corresponding to 20 mg dry matter. The loaded DEAE-Sephadex is filtered off and cleaned by resuspending in washing buffer.
- DEAE-Sephadex is suspended in 1 ml elution buffer and 15 min. protected at room temperature telt.
- the solution of the partial prothrombin complex is dialyzed overnight against distilled water that has been pre-cooled to 4 ° C. and frozen in portions.
- a suitable dilution of the PPK according to point 2 must be determined in the thrombin formation test (see point 5).
- HEPES buffer eg 1:20, 1:40 and 1:80
- HEPES N- (2-hydroxyethyl) piperazine-N '- (2-ethanesulfonic acid
- a suitable dilution is characterized by the linearity of the rate of cleavage of the chromogenic substrate S 2238.
- the ready-to-use APK can be frozen in portions. With this procedure, an APK can be reproducibly produced with a factor Xa content of approximately 1% of the total amount of factor X in the preparation. Thrombin is not detectable after incubation of the APK with the chromogenic substrate S 2238.
- Dialysis tubing cellulose membrane from Sigma (Art. No. D 9402) or Slide-A-Lyzer TM dialysis cassette from Fa.
- Phosphatidylserine (Sigma Art. No. P 1185) Phosphatidylcholm (PC), (Sigma Art. No. P 4139).
- Both phospholipids can contain unsaturated, but preferably saturated fatty acids;
- Dialysis buffer in the form of 94.5 g sucrose and 0.27 g NaCl per liter dist. Water.
- the dialysis buffer can also contain 0.5% NaN 3.
- acetone dry powder is digested with 1 ml of the 10% octyl glucoside solution while shaking at about 30 ° C in an ultrasonic bath.
- the insoluble material is removed by centrifugation, 20 mg of phospholipidic solution (molar ratio PC to PS 6 to 4) is dissolved per ml of supernatant and dialyzed against the dialysis buffer.
- dialysis buffer which contains a gel for binding detergents (e.g. Biorad SM-2).
- the detergent is removed by dialysis, and a suspension of vesicles is spontaneously formed, which contain the tissue factor integrated.
- the vesicles obtained can be frozen in portions.
- a suitable dilution is sought based on the blank value in the thrombin formation test (see point 5), the blank value being supposed to be a delta OD of 0.005 to 0.010.
- HEPES / NaCl buffer 6 M HEPES, 139 M NaCl, 3.5 g albumin per 1 buffer, pH 7.35;
- Citrate buffer 20 mM Na 3 citrate 2 H20, 125 mM NaCl, pH 7.35;
- Plasma test for the presence of activated coagulation factors Pooled plasma, produced either from whole blood or by plasmapheresis, is treated with 1% Triton X-100 and 1% tributyl phosphate in a known manner to inactivate membrane-enveloped viruses (Neurath, AR and Horowitz, B., EP-PS
- Chro ogenes substrate S 2238, Chro ogenix, Art. No. 41202 The content of a vial S 2238 (25 mg) is in 20 ml dist. Water dissolved; by dilution in the ratio l + i with dist. Water is made to a working dilution of 1 mM. Thrombin, 53 nkat, Chro Ogenix, Art. No. 41217, is in 1 ml of dist. Water dissolved. A buffer concentrate
- a working buffer is made by mixing buffer concentrate (30 ml) with human serum albumin (HSA), 20% HSA (0.75 ml). This is used to mix substrate buffer containing 26 ml working buffer and 2.4 ml substrate solution.
- HSA human serum albumin
- thrombin formation from activated coagulation factors the values for APK and the blank value are subtracted from the measured extinction difference per minute. Using batch 9 as an example, this results in a value of 0.029.
- a thrombin activity of 2 nkat is read off a calibration line with thrombin dilutions. If plasma samples contain heparin, this must be neutralized with protasulfate or Polybren TM (hexadimethrin bromide) before the test or preferably inactivated with heparinase.
- Factor IXa, factor XIa and factor Xlla were obtained from Alexis, Art. No. 73510-1, 200-039-C025 and 200-042-UCO2. Defibrinated plasma was activated by incubation with thrombin (1.66 nkat, 10 min. At 37 ° C.), then the thrombin activity was increased using Pefabloc SC TM (4- (2-aminoethyl) -benzenesulfonyl fluoride hydrochloride), Boehringer Mannheim , Art. No. 1 429 868, inhibited. The amount of Pefabloc SC TM required to inhibit the thrombin activity presented was determined in a preliminary test.
- factor IXa The manufacturer of factor IXa, factor XIa and factor Xlla only states the activity in plasma units for factor IXa, where 1 plasma unit corresponds to the amount of the factor in 1 ml of normal plasma. Using the pipetting scheme and the test procedure, it can be calculated that 0.003 plasma units of factor IXa in the test trigger a clearly measurable thrombin formation after only 5 minutes of incubation time in the thrombin formation test.
- Factor VIIIa was obtained from Alexis, Art. No. 73560-1 or HF086-1. Defibrinated plasma was not am activated. The pipetting scheme and test procedure were analogous to those given in Example 2. In a direct comparison, factor VIII phospholipid vesicles with and without integrated tissue factor were examined as cofactors in the thrombin formation test. Vesicles without tissue factor were used undiluted, while vesicles with integrated tissue factor had to be prediluted by a factor of 2000. The following results were obtained in such a comparison:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98913654A EP0975975A1 (de) | 1997-04-09 | 1998-03-06 | Verfahren zur bestimmung von aktivierten blutgerinnungsfaktoren in plasma und plasmaderivaten |
CA002286164A CA2286164A1 (en) | 1997-04-09 | 1998-03-06 | Method for determining activated coagulation factors in plasma and plasma derivatives |
US09/402,332 US6124110A (en) | 1997-04-09 | 1998-03-06 | Method for determining activated coagulation factors in plasma and plasma derivatives |
NO994736A NO994736L (no) | 1997-04-09 | 1999-09-29 | Fremgangsmåte for bestemmelse av aktiverte blodkoaguleringsfaktorer i plasma og plasmaderivater |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19714599 | 1997-04-09 | ||
DE19714599.0 | 1997-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998045713A1 true WO1998045713A1 (de) | 1998-10-15 |
Family
ID=7825875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001264 WO1998045713A1 (de) | 1997-04-09 | 1998-03-06 | Verfahren zur bestimmung von aktivierten blutgerinnungsfaktoren in plasma und plasmaderivaten |
Country Status (5)
Country | Link |
---|---|
US (1) | US6124110A (de) |
EP (1) | EP0975975A1 (de) |
CA (1) | CA2286164A1 (de) |
NO (1) | NO994736L (de) |
WO (1) | WO1998045713A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1337660A2 (de) * | 2000-10-27 | 2003-08-27 | BioMerieux, Inc. | Verfahren zur bestimmung globaler gerinnungsfähigkeit und hämostatischen potentials |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247488B2 (en) * | 2003-05-06 | 2007-07-24 | Medtronic, Inc. | Method and kit for testing a multi-channel blood assay cartridge |
US20050221414A1 (en) * | 2004-03-31 | 2005-10-06 | Katalin Varadi | Kit for measuring the thrombin generation in a sample of a patient's blood or plasma |
AT501650A1 (de) * | 2005-02-22 | 2006-10-15 | Technoclone Ges M B H | Verfahren zur bestimmung der gerinnungsaktivierung sowie gerät zur durchführung des verfahrens |
US8071545B2 (en) * | 2005-03-15 | 2011-12-06 | Lewis S. Coleman, Md, Inc. | Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism |
SE1050124A1 (sv) * | 2010-02-08 | 2011-08-09 | Linkoping Biocontrols Ab | Stabil lösning |
EP2576813A1 (de) | 2010-05-28 | 2013-04-10 | Diagon Kft. | Verfahren für die zweiphasige zubereitung von liposomen und anwendung dafür bei der herstellung von diagnostischen reagenzien |
CN107356768A (zh) * | 2017-06-23 | 2017-11-17 | 宁波艾科生物科技有限公司 | 一种液体即用型凝血酶原时间检测试剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472850A (en) * | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3516579A1 (de) * | 1984-11-19 | 1986-05-22 | Boehringer Mannheim Gmbh, 6800 Mannheim | Gerinnungstest auf teststreifen |
DE69632530T2 (de) * | 1995-03-03 | 2005-05-25 | Eisai Co., Ltd. | Prothrombin aktivierendes enzym, das kalzium benötigt |
US5677162A (en) * | 1995-05-01 | 1997-10-14 | New York Blood Center, Inc. | Method for activating prothrombin to thrombin |
-
1998
- 1998-03-06 EP EP98913654A patent/EP0975975A1/de not_active Ceased
- 1998-03-06 WO PCT/EP1998/001264 patent/WO1998045713A1/de not_active Application Discontinuation
- 1998-03-06 CA CA002286164A patent/CA2286164A1/en not_active Abandoned
- 1998-03-06 US US09/402,332 patent/US6124110A/en not_active Expired - Fee Related
-
1999
- 1999-09-29 NO NO994736A patent/NO994736L/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472850A (en) * | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 119, no. 8, 23 August 1993, Columbus, Ohio, US; abstract no. 79925, XP002072370 * |
Y. SULTAN ET AL.: "IN VITRO EVALUATION OF FACTOR VIII- BYPASSING ACTIVITY OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE, PROTHROMBIN COMPLEX CONCENTRATE AND FACTOR VIIa IN THE PLASMA OF PATIENTS WITH FACTOR VIII INHIBITORS : THROMBIN GENERATION TEST IN THE PRESENCE OF COLLAGEN-ACTIVATED PLATELETS.", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 121, no. 3, 1993, NEW YORK NY USA, pages 444 - 452 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1337660A2 (de) * | 2000-10-27 | 2003-08-27 | BioMerieux, Inc. | Verfahren zur bestimmung globaler gerinnungsfähigkeit und hämostatischen potentials |
EP1337660A4 (de) * | 2000-10-27 | 2005-08-17 | Bio Merieux Inc | Verfahren zur bestimmung globaler gerinnungsfähigkeit und hämostatischen potentials |
Also Published As
Publication number | Publication date |
---|---|
US6124110A (en) | 2000-09-26 |
NO994736D0 (no) | 1999-09-29 |
NO994736L (no) | 1999-09-29 |
EP0975975A1 (de) | 2000-02-02 |
CA2286164A1 (en) | 1998-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69919702T2 (de) | Verfahren zur Bestimmung der Blutgerinnung in Plasma | |
EP0203509B1 (de) | Verfahren zur quantitativen Bestimmung von Protein C und Aktivatorpräparat zur Durchführung des Verfahrens | |
DE60024669T2 (de) | Hämatologische bestimmung und reagenz | |
EP0915340B1 (de) | Verfahren zur Bestimmung des antikoagulatorischen Potentials einer Probe und Verfahren zur Bestimmung der Glykosilierung von Thrombomodulin | |
EP0236985B1 (de) | Verfahren zur photometrischen Bestimmung der Protein C- und/oder Protein S-Aktivität | |
CH635747A5 (de) | Verfahren zur herstellung einer blutgerinnungsfoerdernden praeparation aus menschlichem blutplasma. | |
EP0711838B2 (de) | Verfahren zum spezifischen Nachweis eines aktivierten Gerinnungsfaktors V mit einer erhöhten Stabilität gegenüber aktiviertem Protein C | |
WO2000046602A2 (de) | Verfahren zur bestimmung der konzentration von thrombininhibitoren | |
JPH06509479A (ja) | 血小板活性の測定 | |
EP0696642B1 (de) | Verfahren zum Nachweis von Störungen des Protein C/Protein S-Systems | |
EP2465942A1 (de) | Verfahren zur simultanen Bestimmung mehrerer Gerinnungsproteasen | |
DE112006003476T5 (de) | Verfahren und Systeme zum Nachweisen und Quantifizieren indirekter Thrombininhibitoren | |
DE2734427C3 (de) | Verfahren zur Gewinnung von thrombinartigen Enzymen aus Schlangengiften | |
EP0975975A1 (de) | Verfahren zur bestimmung von aktivierten blutgerinnungsfaktoren in plasma und plasmaderivaten | |
EP0003474A1 (de) | Verfahren zur Prothrombin-Bestimmung, dazu verwendetes Reagenz und Verfahren zur Herstellung eines Faktor-Xa-Präparats | |
AT395597B (de) | Reagens zur bestimmung von faktor viii-aktivitaet | |
EP0062310B1 (de) | Reagens zur optischen Bestimmung des Blutgerinnungsverhaltens | |
EP0972203B1 (de) | REAGENS ZUR BESTIMMUNG DER aPTT | |
DE19714559C1 (de) | Verfahren zur Bestimmung von aktivierten Blutgerinnungsfaktoren in Plasma und Plasmaderivaten | |
EP0570355B1 (de) | Verwendung von Prothrombinfragmenten | |
EP0182929A1 (de) | Koaktivator zur Aktivierung von Protein C | |
DE69916816T2 (de) | Verbesserter blutgerinnungstest | |
EP1853925A1 (de) | Verfahren zur bestimmung der gesamtgerinnungsaktivität einer blut- oder plasmaprobe | |
AT403437B (de) | Physiologisch aktive gewebefaktor-präparation | |
WO2001073445A2 (de) | Verfahren zur bestimmung von löslichem fibrin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998913654 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2286164 Country of ref document: CA Ref country code: CA Ref document number: 2286164 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09402332 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998913654 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1998913654 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998913654 Country of ref document: EP |